Challenges of sharing individual participant data for secondary research on neglected tropical diseases: the experience of Drugs for Neglected Diseases initiative and a call for action

by Tarwid JChilds MJunod-Moser D, Negrouk A, Egondi TTipple C. BMJ Open 2024, 14:e078862. doi: 10.1136/bmjopen-2023-078862

Summary: DNDi is committed to maximising the scientific value of the individual participant data (IPD) it collects, while ensuring participant privacy and transparency in data processing. The authors of this article share what DNDi has learnt while working on its commitment to data sharing and aim to advance the debate about best practice to avoid ‘IPD sharing paralysis’, especially in multistakeholder projects across diverse regulatory environments. A case study outlines the ethical, legal and technical challenges, revealing that each research project presents unique obstacles that delay data sharing and increase costs. The authors conclude that a case-by-case approach is required for each IPD project to balance individual rights, research integrity and the maximum use of IPD for scientific progress.

The post Challenges of sharing individual participant data for secondary research on neglected tropical diseases: the experience of Drugs for Neglected Diseases initiative and a call for action first appeared on DNDi.

Ajude os pacientes negligenciados

Até o momento, desenvolvemos nove tratamentos para doenças negligenciadas, salvando milhões de vidas. Temos o objetivo de disponibilizar 25 novos tratamentos em nossos primeiros 25 anos. Você pode nos ajudar!

Organização internacional, sem fins lucrativos, que desenvolve tratamentos seguros, eficazes e acessíveis para os pacientes mais negligenciados.

DNDi Global

Entre em contato

DNDi pelo mundo

Apoie a DNDi

Faça uma doação!

Trabalhe conosco

Oportunidades

Exceto para imagens, filmes e marcas registradas que estão sujeitos aos Termos de Uso da DNDi, o conteúdo deste site está licenciado sob uma Licença Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License.